gener
structur
glycoform
spike
protein
base
report
structur
protein
report
glycom
data
protein
produc
cell
also
report
structur
glycoform
repres
present
nascent
glycoprotein
prior
enzymat
modif
golgi
er
well
commonli
observ
antigen
present
virus
model
subject
md
simul
take
account
protein
glycan
plastic
determin
extent
glycan
microheterogen
impact
antigen
lastli
identifi
peptid
protein
like
present
human
leukocyt
antigen
hla
complex
discuss
role
protein
glycosyl
potenti
modul
adapt
immun
respons
viru
relat
vaccin
present
pandem
led
million
confirm
infect
fatal
rate
approxim
percent
sinc
first
report
sever
acut
respiratori
syndrom
sar
infect
novel
coronaviru
end
april
still
vaccin
approv
therapeut
treat
diseas
examin
structur
envelop
spike
protein
mediat
host
cell
infect
specif
focu
extent
protein
glycosyl
mask
viru
antigen
host
immun
respons
viral
envelop
protein
often
modifi
attach
complex
glycan
account
half
molecular
weight
glycoprotein
hiv
glycosyl
surfac
antigen
help
pathogen
evad
recognit
host
immun
system
cloak
protein
surfac
detect
antibodi
influenc
abil
host
rais
effect
adapt
immun
respons
even
exploit
viru
enhanc
infect
fortun
innat
immun
system
evolv
rang
strategi
respond
glycosyl
pathogen
antigen
glycosyl
nevertheless
complic
develop
vaccin
time
protein
sequenc
viral
antigen
undergo
mutat
alter
speci
specif
viru
modul
infect
alter
antigen
surfac
protein
mutat
also
impact
degre
protein
glycosyl
creat
new
remov
exist
locat
glycan
glycosit
antigen
vari
surfac
antigen
glycosyl
thu
mechan
new
viru
strain
evad
host
immun
respons
attenu
efficaci
exist
vaccin
recent
cryoem
structur
glycoprotein
report
led
conclus
like
relat
protein
sar
pandem
protein
also
extens
glycosyl
furthermor
analysi
glycan
structur
present
glycosit
protein
produc
recombinantli
human
embryon
kidney
cell
also
recent
report
gener
structur
sever
glycoform
glycoprotein
glycan
repres
present
protein
produc
cell
well
correspond
nascent
glycoprotein
prior
enzymat
modif
golgi
well
commonli
observ
antigen
present
virus
subject
model
long
md
simul
compar
extent
glycan
microheterogen
impact
epitop
exposur
addit
identifi
peptid
protein
like
present
human
leukocyt
antigen
hla
complex
discuss
role
protein
glycosyl
modul
adapt
immun
respons
viru
relat
vaccin
impact
glycosyl
abil
antibodi
bind
pathogen
glycoprotein
may
estim
quantifi
fraction
surfac
area
protein
antigen
physic
shield
glycan
antibodi
recognit
analyt
approach
defin
glycoprotein
antigen
led
conclus
glycosyl
envelop
protein
hepat
c
viru
reduc
surfac
area
structur
protein
may
readili
determin
experiment
use
techniqu
xray
crystallographi
cryoelectron
microscopi
cryoem
howev
far
challeng
determin
structur
glycan
glycan
often
significantli
flexibl
protein
attach
also
multipl
differ
glycan
structur
may
present
given
glycosit
give
rise
ensembl
glycosyl
protein
variant
glycoform
glycan
heterogen
natur
result
mechan
protein
glycosyl
glycan
ad
protein
attach
asparagin
side
chain
nlink
glycan
transfer
en
bloc
singl
glycan
precursor
structur
subsequ
passag
nascent
glycoprotein
cellular
machineri
endoplasm
reticulum
golgi
apparatu
expos
glycan
enzym
glycosidas
glycosyl
transferas
modifi
structur
abil
enzym
alter
process
glycan
depend
part
shape
protein
glycan
attach
particularli
region
glycosit
time
given
glycan
expos
enzym
presenc
multipl
glycosit
variat
composit
glycan
glycosit
result
stagger
number
permut
protein
glycoform
although
particular
structur
glycan
glycosit
may
impact
protein
immunogen
report
case
hepat
c
viru
locat
number
densiti
glycosit
profound
impact
innat
immun
respons
viru
antigen
viral
envelop
protein
observ
case
influenza
lastli
complic
understand
effect
glycosyl
protein
antigen
glycan
display
larg
intern
motion
prevent
accur
descript
singl
shape
contrast
protein
fortun
comput
simul
play
key
role
character
glycoprotein
predict
like
shape
glycan
typic
simul
glycan
ad
experimentallydetermin
structur
protein
result
static
model
glycoprotein
subject
molecular
dynam
md
simul
approxim
effect
water
temperatur
tempor
spatial
properti
glycoprotein
simul
time
frame
structur
obtain
simul
use
determin
extent
glycosyl
alter
protein
antigen
properti
structur
specif
glycan
particular
glycosit
known
glycan
employ
simul
howev
data
often
unavail
plausibl
glycosyl
state
may
assum
particularli
case
protein
multipl
permut
glycoform
well
establish
strong
depend
composit
rel
glycan
abund
glycan
microheterogen
cell
type
use
glycoprotein
product
larg
bodi
data
relat
influenc
host
cell
line
viral
envelop
protein
glycosyl
exampl
glycom
analysi
influenza
viru
produc
five
differ
cell
line
relev
vaccin
product
let
observ
profound
differ
composit
glycan
given
site
structur
vari
paucimannos
cell
corefucosyl
hybrid
bisect
nacetylglucosamin
egg
sialyl
biantennari
glycan
reason
model
glycoprotein
report
sitespecif
glycosyl
well
hypothet
homogen
glycosyl
glycoform
high
mannos
paucimannos
biantennari
complex
complex
corefucosyl
biantennari
complex
complex
core
f
type
comparison
among
glycoform
permit
assess
impact
cellbas
differenti
glycan
process
protein
antigen
notabl
differ
glycan
microheterogen
shown
significantli
affect
potenc
influenza
antigen
determin
singl
radial
immunodiffus
srid
assay
assay
typic
use
measur
potenc
commerci
influenza
vaccin
precis
composit
glycan
may
alter
antigen
suggest
glycan
microheterogen
may
heavili
impact
expos
surfac
area
protein
nevertheless
glycan
variat
shown
impact
abil
innat
immun
lectin
surfact
proteind
spd
respond
antigen
spd
requir
cluster
high
mannos
glycan
pathogen
protein
order
bind
variat
glycan
composit
impair
respons
case
influenza
increas
number
glycosit
shown
impact
receptor
bind
protein
fold
virul
antigen
shield
immunogen
site
assess
impact
glycosyl
protein
antigen
initi
comparison
more
character
coronavirus
undertaken
comparison
epitop
relat
coronaviru
glycoprotein
viral
adhes
host
cell
enabl
protein
viru
surfac
envelop
evolv
recogn
specif
receptor
host
cell
receptor
may
glycan
well
known
case
influenza
endem
human
cov
merscov
protein
case
current
virus
human
immunodefici
viru
hiv
receptor
bind
domain
rbd
within
domain
protein
shown
interact
host
protein
angiotensinconvert
enzym
affin
enabl
viru
adher
infect
host
cell
expos
viral
surfac
protein
major
target
host
antibodi
refer
viral
antigen
antigen
therefor
target
vaccin
develop
glycoprotein
share
high
degre
structur
similar
averag
rootmeansquar
differ
rmsd
posit
also
share
rel
high
sequenc
homolog
mer
glycoprotein
also
share
similar
trimer
structur
cryoem
studi
show
receptor
bind
domain
subunit
glycoprotein
exist
least
two
conform
undergo
hingelik
movement
also
report
mer
well
distantli
relat
coronavirus
despit
structur
sequenc
similar
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
glycoprotein
sequenc
base
epitop
predict
indic
approxim
theoret
sequenti
epitop
uniqu
two
protein
better
understand
antigen
properti
protein
structur
perspect
align
structur
glycoprotein
cocryst
structur
mer
contain
bound
antibodi
fragment
align
extent
epitop
glycoprotein
might
inaccess
known
antibodi
basi
structur
differ
glycoprotein
due
shield
glycan
glycoprotein
surfac
figur
infer
previous
report
antibodi
bind
almost
exclus
rbd
align
glycosyl
protein
evid
approxim
correspond
mer
epitop
shield
glycan
antibodi
bind
glycoprotein
area
protein
surfac
apex
domain
appear
access
known
antibodi
epitop
surfac
area
known
antibodi
cocomplex
rang
approxim
compar
contact
surfac
glycoprotein
receptor
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
preliminari
epitop
analysi
take
account
variat
sitespecif
glycan
composit
plastic
glycan
protein
furthermor
number
antibodi
cocrystal
relat
protein
repres
minut
fraction
possibl
repertoir
address
limit
subject
multipl
glycoform
glycoprotein
md
simul
interpret
result
term
impact
glycan
structur
theoret
glycoprotein
antigen
surfac
area
figur
estim
antibodi
access
surfac
area
abasa
spheric
probe
deriv
radiu
smaller
sphere
approxim
averag
size
hypervari
loop
four
antibodi
epitop
either
protein
surfac
residu
pdb
id
carbohydr
protein
residu
probe
size
may
compar
valu
employ
previous
estim
antigen
surfac
area
chang
solvent
access
surfac
area
sasa
show
shield
glycan
thu
simpl
sasa
model
use
analysi
addit
account
presenc
betasheet
framework
antibodi
variabl
fragment
fv
introduc
second
larger
probe
suffici
approxim
enclos
domain
antigen
surfac
area
defin
sum
surfac
area
protein
residu
make
contact
cdr
probe
provid
cdr
probe
proxim
residu
access
fv
probe
latter
requir
govern
lmax
requir
distanc
cdrantigen
contact
site
fv
probe
surfac
less
length
longest
cdr
loop
mab
chosen
refer
contain
particularli
long
cdr
loop
penetr
glycan
shield
imag
gener
ucsf
chimera
three
independ
md
simul
five
glycoform
protein
perform
combin
total
per
glycoform
use
comput
extent
antigen
surfac
area
sensit
glycan
microheterogen
tabl
data
indic
uniform
glycosyl
smallest
glycan
paucimannos
substructur
within
nlink
glycan
provid
least
shield
protein
surfac
leav
surfac
expos
antibodi
probe
contrast
largest
high
mannos
nlink
glycan
correspond
nascent
glycoform
would
exist
prior
process
endoplasm
reticulum
golgi
apparatu
led
highest
level
surfac
shield
extent
shield
offer
two
complex
type
glycan
statist
differ
antigen
surfac
exposur
sitespecif
model
gener
commonli
observ
glycan
glycosit
glycoprotein
produc
recombinantli
cell
also
includ
comparison
glycoform
result
shield
protein
antigen
surfac
valu
similar
model
base
uniform
complex
glycan
result
broadli
consist
conclus
antigen
protein
insensit
glycan
microheterogen
except
glycoform
compos
sole
glycan
nevertheless
differ
glycosyl
may
impact
featur
local
interact
glycan
protein
surfac
local
structur
fluctuat
either
protein
glycan
conform
partial
captur
crd
probe
analysi
visual
examin
structur
md
simul
figur
broadli
confirm
observ
figur
expos
epitop
compris
receptor
site
specif
apex
region
domain
domain
open
conform
moreov
extens
motion
display
glycan
illustr
singl
static
model
fulli
captur
extent
glycan
shield
also
observ
ring
antigen
site
appear
encircl
domain
independ
glycoform
unlik
extrem
high
level
glycan
shield
challeng
hiv
vaccin
develop
level
shield
glycan
protein
moder
approxim
surfac
potenti
access
antibodi
tabl
detail
protein
surfac
color
accord
antibodi
access
black
red
least
access
imag
gener
use
visual
molecular
dynam
vmd
version
adapt
immun
respons
beyond
role
shield
underli
protein
recognit
antibodi
glycan
pathogen
protein
may
also
attenu
abil
host
immun
system
rais
antibodi
epitop
includ
glycan
tcell
depend
adapt
immun
respons
peptid
endocytos
pathogen
present
antigen
present
cell
major
histocompat
complex
ii
molecul
known
human
leukocyt
antigen
hla
complex
hla
complex
prefer
peptid
motif
base
knowledg
prefer
possibl
predict
peptid
protein
like
hla
antigen
howev
peptid
contain
glycosyl
site
abil
peptid
present
hla
complex
may
compromis
exampl
peptid
bind
hla
molecul
due
steric
presenc
glycan
howev
glycopeptid
may
present
hla
complex
glycan
small
enough
found
end
peptid
antigen
nt
interfer
hla
bind
glycanmedi
shield
predict
hla
antigen
tabl
deriv
protein
shown
figur
hla
peptid
sequenc
also
contain
glycosit
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
sequenc
protein
ncbi
use
gener
model
glycoprotein
residu
includ
structur
due
lack
relev
templat
structur
sequenc
within
rectangl
predict
consist
one
hla
antigen
use
rankpep
server
imedmeducmestoolsrankpep
glycosit
indic
asterisk
residu
report
interact
receptor
underlin
proteas
cleavag
site
indic
triangl
rs
junction
sequenc
color
accord
antibodi
access
comput
sitespecif
glycoform
white
red
least
access
b
antibodi
access
comput
nonglycosyl
protein
c
differ
access
sitespecif
nonglycosyl
glycoform
plot
fold
chang
antigen
access
simul
blue
white
blue
indic
glycosylationdepend
surfac
shield
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
expect
glycosyl
consist
decreas
surfac
exposur
residu
proxim
glycosit
figur
c
also
led
nonsequenti
chang
exposur
result
topolog
vicin
glycosit
glycosit
structur
predict
present
hla
peptid
although
glycan
may
occur
throughout
hla
sequenc
tabl
sequenc
glycan
predict
present
terminu
least
one
put
hla
antigen
observ
suggest
glycosit
may
interfer
antigen
present
hla
complex
properti
essenti
potenti
gener
antibodi
underli
epitop
moreov
may
lead
antibodi
target
carbohydr
glycoprotein
anticarbohydr
antibodi
shown
neutral
virus
hiv
therefor
glycosyl
peptid
offer
altern
tradit
peptid
epitop
perspect
vaccin
develop
target
glycan
epitop
would
expect
benefit
match
glycan
microheterogen
vaccin
circul
viru
requir
addit
consider
choic
cell
type
vaccin
product
present
studi
indic
glycan
shield
approxim
underli
protein
surfac
glycoprotein
antibodi
recognit
valu
rel
insensit
glycan
type
suggest
although
glycan
microheterogen
vari
accord
host
cell
type
efficaci
antisera
impact
differ
contrast
analog
influenza
hemagglutinin
variat
glycosit
locat
aris
antigen
drift
expect
profound
effect
protein
antigen
potenti
vaccin
efficaci
fortun
access
largest
antigen
surfac
protein
consist
bind
domain
viru
ca
nt
exploit
glycan
shield
mutat
chang
evad
host
immun
respons
without
potenti
attenu
viral
fit
requir
viru
maintain
integr
rbd
suggest
vaccin
includ
epitop
may
effect
long
viru
continu
target
host
receptor
glycan
microheterogen
may
impact
innat
immun
respons
alter
abil
collectin
lectin
immun
system
neutral
viru
may
impact
adapt
immun
respons
alter
number
viabl
hla
antigen
heterogen
littl
impact
antigen
surfac
area
protein
vaccin
perspect
efficaci
may
benefit
ensur
product
method
result
glycosyl
profil
match
circul
viru
engin
vaccin
avoid
glycosyl
sequenc
lastli
observ
homogen
glycosyl
glycoform
predict
display
approxim
antigen
properti
comput
relev
sitespecif
glycoform
suggest
model
use
appli
advanc
report
experiment
glycom
data
final
conclus
signific
enabl
effect
glycosit
alter
estim
anticip
antigen
shift
drift
spike
protein
structur
structur
prefus
form
protein
refseq
uniprot
base
cryoem
structur
pdb
code
obtain
swissmodel
server
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
swissmodelexpasyorg
model
coverag
residu
protein
protein
glycoform
gener
five
uniqu
model
glycosyl
glycoprotein
gener
use
glycoprotein
builder
avail
glycamweb
wwwglycamorg
togeth
inhous
program
adjust
asparagin
side
chain
torsion
angl
glycosid
linkag
within
known
lowenergi
rang
reliev
atom
overlap
core
protein
describ
previous
site
specif
glycan
use
model
glycoform
repres
data
obtain
glycoprotein
express
cell
present
tabl
energi
minim
molecular
dynam
md
simul
glycosyl
structur
place
period
box
approxim
water
molecul
buffer
glycoprotein
box
edg
energi
minim
atom
perform
step
steepest
decent
follow
conjug
gradient
constant
pressur
atm
temperatur
k
npt
condit
md
simul
perform
npt
condit
cuda
implement
pmemd
simul
code
present
softwar
suit
forc
field
forc
field
employ
carbohydr
protein
moieti
respect
berendsen
barostat
time
constant
ps
employ
pressur
regul
langevin
thermostat
collis
frequenc
ps
employ
temperatur
regul
nonbond
interact
cutoff
employ
longrang
electrostat
treat
particlemesh
ewald
pme
method
coval
bond
involv
hydrogen
constrain
shake
algorithm
allow
integr
time
step
fs
employ
energi
minim
coordin
equilibr
ps
restraint
solut
heavi
atom
system
equilibr
restraint
atom
protein
prior
initi
independ
product
md
simul
random
start
seed
total
time
restraint
appli
coordin
pdb
format
glycoform
made
avail
download
glycamweb
wwwglycamorg
